Informations générales (source: ClinicalTrials.gov)
Assessment of HGI (Hemoglobin Glycation Index) Variability Over Time in Patients Living with Diabetes Using Continuous Glucose Monitoring (GAP OUEST)
Interventional
N/A
Nantes University Hospital (Voir sur ClinicalTrials)
juin 2024
septembre 2027
05 avril 2025
The goal of this clinical trial is to learn about the variability of HGI (Hemoglobin
Glycation Index) over time in patients living with diabetes using a continuous glucose
monitoring.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | CAMPINOS Catherine | 14/02/2025 09:03:16 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CH de La Rochelle - 17019 - La Rochelle - France | Didier GOUET | Contact (sur clinicalTrials) | |||
| CH du Mans - 72037 - Le Mans - France | Charly VAILLANT | Contact (sur clinicalTrials) | |||
| CHU d'Angers - 49100 - Angers - France | Claire BRIET | Contact (sur clinicalTrials) | |||
| CHU de Brest - 29200 - Brest - France | Philippe THUILLIER | Contact (sur clinicalTrials) | |||
| CHU de Caen - 14033 - Caen - France | Michael JOUBERT | Contact (sur clinicalTrials) | |||
| CHU de Nantes - 44093 - Nantes - France | Hélène AUFFRET | Contact (sur clinicalTrials) | |||
| CHU de Poitiers - 86021 - Poitiers - France | Pierre Jean SAULNIER | Contact (sur clinicalTrials) | |||
| CHU de Rennes - 35000 - Rennes - France | Agathe GUENEGO | Contact (sur clinicalTrials) | |||
| CHU de Toulouse - 31059 - Toulouse - France | Pierre GOURDY | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Major (adult subject over 18), with no upper age limit
- Enrolled in a social security scheme or beneficiary of such a scheme
- Agreement to participate (informed, written consent)
- Established diabetes (regardless the type of diabetes), known for at least 6 months
at inclusion
- Regular user of a glucose monitoring system for at least 3 months.
Non inclusion Criteria:
- Known hemoglobinopathy
- Inadequate use of the flash glucose monitoring system with a capture rate of less
than 70% of interstitial glucose measurements, during the 3 months preceding the
inclusion visit.
- Stage 5 renal insufficiency (CKD-EPI less than 15 mL/min/1.73 m2)
- Pregnant or breast-feeding
- Major under guardianship, curatorship or safeguard of justice
- Any situation assessed by the investigator as potentially prejudicial to the
participant's health as a result of participation in the study
- Major (adult subject over 18), with no upper age limit
- Enrolled in a social security scheme or beneficiary of such a scheme
- Agreement to participate (informed, written consent)
- Established diabetes (regardless the type of diabetes), known for at least 6 months
at inclusion
- Regular user of a glucose monitoring system for at least 3 months.
Non inclusion Criteria:
- Known hemoglobinopathy
- Inadequate use of the flash glucose monitoring system with a capture rate of less
than 70% of interstitial glucose measurements, during the 3 months preceding the
inclusion visit.
- Stage 5 renal insufficiency (CKD-EPI less than 15 mL/min/1.73 m2)
- Pregnant or breast-feeding
- Major under guardianship, curatorship or safeguard of justice
- Any situation assessed by the investigator as potentially prejudicial to the
participant's health as a result of participation in the study
- Treatment with corticosteroids in the 3 months preceding the visit
- Unusual acute situation (infection, very unusual physical activity, etc.) deemed
significant by the investigator
- Pregnancy started